Management of asthma and allergic rhinitis in children during the COVID-19 pandemic Artykuł przeglądowy

##plugins.themes.bootstrap3.article.main##

Andrzej Emeryk
Ewelina Wawryk-Gawda
Kamil Janeczek

Abstrakt

The aim of the study was to present current data on the treatment of children with asthma and allergic rhinitis during the COVID-19 pandemic. To this end, the available literature was reviewed (until 2020, June 1st).

Pobrania

Dane pobrania nie są jeszcze dostepne

##plugins.themes.bootstrap3.article.details##

Jak cytować
Emeryk A., Wawryk-Gawda E., & Janeczek K. (2020). Management of asthma and allergic rhinitis in children during the COVID-19 pandemic. Alergoprofil, 16(2), 8-15. https://doi.org/10.24292/01.AP.162300620
Dział
THERAPY

Bibliografia

1. Pyrć K. SARS-CoV-2. Klinika Nowa. 2020; 27(1): 9-14.
2. Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020; 30(7): 1346-51.
3. Geller C, Varbanov M, Duval RE. Human coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategies. Viruses. 2012; 4(11): 3044‐68.
4. Zimmermann P, Curtis N. Coronavirus infections in children including COVID-19: an overview of the epidemiology, clinical features, diagnosis, treatment and prevention options in children. Pediatr Infect Dis J. 2020; 39(5): 355‐68.
5. Grzesiowski P. Pandemia COVID-19 – epidemiologia, patofizjologia, aspekty kliniczne. Klinika Nowa. 2020; 27(1): 4-8.
6. She J, Liu L, Liu W. COVID-19 epidemic: Disease characteristics in children. J Med Virol. 2020; 92(7): 747-54. http://doi.org/10.1002/jmv.25807.
7. Dong Y, Mo X, Hu Y et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020; 145(6): e20200702.
8. Lu X, Zhang L, Du H et al. SARS-CoV-2 infection in children. N Engl J Med. 2020; 382(17): 1663‐5.
9. Gudbjartsson DF, Helgason A, Jonsson H et al. Spread of SARS-CoV-2 in the Icelandic population. N Engl J Med. 2020; 382: 2302-15.
10. CDC COVID-19 Response Team. Coronavirus disease 2019 in children – United States, February 12 – April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(14): 422‐6.
11. Cai J, Xu J, Lin D et al. A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis. 2020: ciaa198.
12. Zhang JJ, Dong X, Cao YY et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. http://doi.org/10.1111/all.14238.
13. Pathak EB, Salemi JL, Sobers N et al. COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020. J Public Health Manag Pract. 2020; 26(4): 325‐33.
14. Tagarro A, Epalza C, Santos M et al. Screening and severity of coronavirus disease 2019 (COVID-19) in Children in Madrid, Spain. JAMA Pediatr. 2020: e201346.
15. Tezer H, Bedir Demirdağ T. Novel coronavirus disease (COVID- 19) in children. Turk J Med Sci. 2020; 50(SI-1): 592‐603.
16. Nathan N, Prevost B, Corvol H. Atypical presentation of COVID-19 in young infants. Lancet. 2020; 395(10235): 1481.
17. See KC, Liew SM, Ng DCE et al. COVID-19: four paediatric cases in Malaysia. Int J Infect Dis. 2020; 94: 125‐7.
18. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr. 2020; 109(6): 1088-95.
19. Zheng F, Liao C, Fan QH et al. Clinical characteristics of children with coronavirus disease 2019 in Hubei, China. Curr Med Sci. 2020; 40(2): 275‐80.
20. Streng A, Hartmann K, Armann J et al. COVID-19 in hospitalized children and adolescents. Monatsschr Kinderheilkd. 2020; http://10.1007/s00112-020-00919-7.
21. Xing Y, Ni W, Wu Q et al. Dynamics of faecal SARS-CoV-2 in infected children during the convalescent phase. J Infect. 2020; S0163-4453(20)30177-8.
22. Ong SWX, Tan YK, Chia PY et al. Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA. 2020; 323(16): 1610‐12.
23. Ng K, Poon BH, Kiat Puar TH et al. COVID-19 and the risk to health care workers: a case report. Ann Intern Med. 2020; 172(11): 766‐7.
24. Abrams EM, Szefler SJ. Managing asthma during coronavirus disease-2019: an example for other chronic conditions in children and adolescents. J Pediatr. 2020; S0022-3476(20)-30528-X.
25. Zheng XY, Xu YJ, Guan WJ et al. Regional, age and respiratory- secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018; 163(4): 845‐53.
26. Brough HA, Kalayci O, Sediva A et al. Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – the 2020 COVID-19 pandemic. A statement from the EAACI‐section on pediatrics. Pediatr Allergy Immunol. 2020; http://doi.org/10.1111/pai.13262.
27. Qin C, Zhou L, Hu Z et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis. 2020; ciaa248.
28. de Lucena TMC, da Silva Santos AF, de Lima BR et al. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020; 14(4): 597‐600.
29. Chen J, Zhang ZZ, Chen YK et al. The clinical and immunological features of pediatric COVID-19 patients in China. Genes Dis. 2020; http://doi.org/10.1016/j.gendis.2020.03.008.
30. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect. 2020; 80(6): 607‐13.
31. Jackson DJ, Busse WW, Bacharier LB et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020; S0091- 6749(20)30551-0.
32. Guan WJ, Ni ZY, Hu Y et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382(18): 1708‐20.
33. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020, 35(10): e112.
34. Lu X, Xiang Y, Du H et al. SARS-CoV-2 infection in children – understanding the immune responses and controlling the pandemic. Pediatr Allergy Immunol. 2020. http://doi.org/10.1111/pai.13267.
35. Shaker MS, Oppenheimer J, Grayson M et al. COVID-19: pandemic contingency planning for the allergy and immunology clinic. J Allergy Clin Immunol Pract. 2020; 8(5): 1477‐88.
36. Kowalski ML, Bartuzi Z, Bręborowicz A et al. Stanowisko grupy ekspertów Polskiego Towarzystwa Alergologicznego w sprawie postępowania u chorych na astmę i choroby alergiczne w okresie pandemii SARS-CoV-2 (Position statement of expert panel of the Polish Allergology Society on the management of patients with bronchial asthma and allergic diseases during SARS-CoV-2 pandemics). Alergia Astma Immunologia. 2020; 25(1): 2-7.
37. Samoliński B, Majsiak E, Madej M. Strategia diagnozowania alergii BOTTOM-UP w okresie zagrożenia epidemicznego wirusem SARS-CoV-2 powodującego chorobę COVID-19. Alergia. 2020; 1(83): 16-20.
38. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2019. (Access: 30.05.2020).
39. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Update 2020. (Access: 30.05.2020).
40. Yamaya M, Nishimura H, Nadine L et al. Formoterol and budesonide inhibit rhinovirus infection and cytokine production in primary cultures of human tracheal epithelial cells. Respir Investig. 2014; 52(4): 251‐60.
41. Yamaya M, Nishimura H, Deng X et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020; 58(3): 155‐68.
42. Abrams EM, Jong GW, Yang CL. Asthma and COVID-19. CMAJ. 2020; 192(20): E551.
43. Levin M, Ansotegui IJ, Bernstein J et al. Acute asthma management during SARS-CoV2-pandemic 2020. World Allergy Organ J. 2020; 13(5): 100125.
44. Pirożyński M. Terapia wziewna – ze szczególnym uwzględnieniem steroidów – w okresie pandemii COVID-19. Alergia. 2020; 1: 4-6.
45. Kuna P. Postępowanie u chorych na astmę lub POChP w dobie epidemii COVID-19. Terapia. 2020; numer specjalny 01: 17-21.
46. Emeryk A, Pirożyński M, Mazurek H et al. Polski przewodnik inhalacyjny. Via Medica, Gdańsk 2015.
47. Doniec Z, Mastalerz-Migas A, Bręborowicz A et al. ReKOMendacje Postępowania w AStmie wczesnodziecięcej dla lekarzy Podstawowej Opieki Zdrowotnej – KOMPAS POZ. Fam Med Prim Care Rev. 2016; 18(2): 181-92.
48. Emeryk A, Pirożyńki M, Mazurek H et al. Stanowisko polskich ekspertów dotyczące nebulizacji w okresie pandemii COVID-19. Terapia. 2020 (in press).
49. Dayal D. We urgently need guidelines for managing COVID- 19 in children with comorbidities. Acta Paediatr. 2020. http://doi.org/10.1111/apa.15304.
50. Calvo C, García López-Hortelano M, de Carlos Vicente JC et al. Recommendations on the clinical management of the COVID-19 infection by the «new coronavirus» SARS-CoV2. Spanish Paediatric Association working group. An Pediatr (Barc). 2020; 92(4): 241.
51. Shen KL, Yang YH, Jiang RM et al. Updated diagnosis, treatment and prevention of COVID-19 in children: experts’ consensus statement (condensed version of the second edition). World J Pediatr. 2020; 1‐8.
52. Şimşek Yavuz S, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50(SI-1): 611‐9.
53. Dong X, Cao YY, Lu XX et al. Eleven faces of coronavirus disease 2019. Allergy. 2020; 00: 1-11.
54. Bousquet J, Akdis C, Jutel M et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: an ARIA-EAACI statement. Allergy. 2020. http://doi.org/ 10.1111/all.14302.
55. Samoliński B, Arcimowicz M. Polskie standardy leczenia nieżytów nosa (PoSLeNN). Alergol Pol. 2013; S1: 1-167.
56. Emeryk A, Rapiejko P. Alergiczny nieżyt nosa. Lekarz POZ. 2019; 5(2): 165-9.